Project Name:	New AI examples from USPTO	**Start Date:**	2024-01-01
Project Number:	2400	**Completion Date:**	2024-12-31

Project Details:

Scientific or Technological Objectives:

The following examples were released during 2024 by the USPTO guidance and training materials on issues relevant to the use of Artificial Intelligence (AI).

https://www.uspto.gov/initiatives/artificial-intelligence/artificial-intelligence-resources

The following examples are reproduced from the original USPTO documents and are intended to be illustrative of claim construcion and analysis for tax credtist, grants or patent eligibility issues. As a result some of the USPTO references have been included (E.G. Step 2A, Prong Two) for user reference.

The first 2 projects address "Subject Matter Eligibility" issues

2401	AI Anomaly detection method
2402	AI Fibrosis Treatment

The following 2 projects address "Inventorship" issues.

2410	Transaxle design using AI - 5 scenarios
2411	Therapeutic cancer compound using AI - 2 scenarios

Field of Science/Technology:

Project Details:

Intended Results:
Work locations:
Key Employees:
Evidence types:

Scientific or Technological Advancement:

Uncertainty #1: Technological uncertainty

Technology or Knowledge Base Level:

Activity #1-1: Activity 1 (Fiscal Year 2024)

Methods of experimentation:

Results:

Conclusion:

Available for public distribution and use.

Project Name:	AI Anomaly detection method	**Start Date:**	2024-01-02
Project Number:	2401	**Completion Date:**	2025-12-23

Project Details:

Scientific or Technological Objectives:

Measurement	Current Performance	Objective	Has results?
New ASIC chip design (synapses/micron)	10	20	Yes
ANN Methodology (x)	(not set)	(not set)	No
Malicious attack detection (%)	97	99.9	Yes

This example illustrates the application of the eligibility analysis to claims that recite limitations specific to artificial intelligence, particularly the use of an artificial neural network to identify or detect anomalies.

[Claim 1] An application specific integrated circuit (ASIC) for an artificial neural network (ANN), the ASIC comprising:
a plurality of neurons organized in an array, wherein each neuron comprises a register, a microprocessor, and at least one input; and a plurality of synaptic circuits, each synaptic circuit including a memory for storing a synaptic weight, wherein each neuron is connected to at least one other neuron via one of the plurality of synaptic circuits.

[Claim 2] A method of using an artificial neural network (ANN) for detecting one or more anomalies in a data set using the trained ANN;

[Claim 3] A method of using an artificial neural network (ANN) to detect malicious network packets dropping the one or more malicious network packets in real time; and blocking future traffic from the source address.

Field of Science/Technology:

Micro-electronics (2.02.03)

Project Details:

Intended Results: Develop new processes, Develop new materials, devices, or products, Improve existing processes
Work locations: Research Facility
Key Employees:
Evidence types:

Scientific or Technological Advancement:

Uncertainty #1: Circuit design HARDWARE

[Claim 1] An application specific integrated circuit (ASIC) for an artificial neural network (ANN), the ASIC comprising:
a plurality of neurons organized in an array, wherein each neuron comprises a register, a microprocessor, and at least one input; and a plurality of synaptic circuits, each synaptic circuit including a memory for storing a synaptic weight, wherein each neuron is connected to at least one other neuron via one of the plurality of synaptic circuits.

In some embodiments, an ANN may be implemented by an application-specific integrated circuit (ASIC). ASICs may be specially customized for a specific artificial intelligence application and provide superior computing capabilities and reduced electricity consumption compared to traditional CPUs

The most significant underlying key variables are:

materials, layouts, connection methods

Technology or Knowledge Base Level:

Available for public distribution and use.

Project Name:	AI Anomaly detection method	**Start Date:**	2024-01-02
Project Number:	2401	**Completion Date:**	2025-12-23

Activity #1-1: Circuit design Eligible for patent (Fiscal Year 2024)

Methods of experimentation:

While the background explains that “[a]n ANN can be realized through software, hardware, or a combination of software and hardware,” the broadest reasonable interpretation of the claimed ANN requires hardware because the claimed ASIC is a physical circuit. The claim recites an ASIC that implements an ANN. The claim is directed to a physical circuit, which is a machine and/or manufacture, and falls within one of the statutory categories of invention.

[Claim 1] An application specific integrated circuit (ASIC) for an artificial neural network (ANN), the ASIC comprising:
a plurality of neurons organized in an array, wherein each neuron comprises a register, a microprocessor, and at least one input; and a plurality of synaptic circuits, each synaptic circuit including a memory for storing a synaptic weight, wherein each neuron is connected to at least one other neuron via one of the plurality of synaptic circuits.

Results:

- New ASIC chip design: 17 synapses/micron (70% of goal)

Conclusion:

The claim recites an ASIC that implements an ANN. The claim is directed to a physical circuit, which is a machine and/or manufacture, and falls within one of the statutory categories of invention.

The claim recites a plurality of neurons, which are hardware components comprising a register and a microprocessor, and a plurality of synaptic circuits which together form an ANN.

The claim does not recite any abstract ideas, such as a mathematical concept, mental process, or a method of organizing human activity, such as a fundamental economic concept or managing interactions between people. See MPEP 2106.04(a)(2).

While ANNs may be trained using mathematics, there is no mathematical concept recited in the claim.

The claim is eligible,

AUTHORS NOTE: THIS OUTLINES THE RELATIVE EASE IN DEFINING TECHNOLOGICAL ADVANCEMENT FOR HARDWARE ITEMS SUCH AS CIRUITS VS. AI PROCESSES WHERE THE "HUMAN" USER INPUT CAN NOT BE CLEARY DEFINED.

Significant variables addressed: connection methods, layouts, materials

Uncertainty #2: ANN design SOFTWARE / AI

ANNs are a type of machine learning model used to perform a wide variety of complex tasks, including image recognition, speech recognition, pattern recognition, and detection of anomalies. An ANN is a biologically inspired algorithm that learns from training data.

An ANN can be realized through software, hardware, or a combination of software and hardware. The structure of an exemplary ANN has a series of layers, each comprising one or more neurons arranged in one or more neuron arrays.

In an exemplary embodiment, a neuron may comprise a register, a microprocessor, and at least one input. Each neuron produces an output, or activation, based on an activation function that uses the outputs of the previous layer and a set of weights as inputs. Each neuron in a neuron array may be connected to another neuron via a synaptic circuit.

A synaptic circuit may include a memory for storing a synaptic weight. An exemplary ANN may be a Deep Neural Network having an input layer, an output layer, and a plurality of fully connected hidden layers. ANNs are particularly useful in anomaly detection because they can effectively extract features in linear and nonlinear relationships.

According to the background section, existing systems use various detection techniques for detecting potentially malicious network packets and can alert a network administrator to potential problems.

A difficulty in anomaly detection is that a system must define the boundary between ordinary and anomalous data and accurately classify data as ordinary or anomalous. The line between ordinary and anomalous data may be difficult to determine with cases approaching a boundary and based on an application-specific domain.

For example, small variations may trigger an identification of an anomaly in network security or medicine while relatively larger deviations may be considered normal in less sensitive applications. Furthermore, malicious actors may attempt to

Available for public distribution and use.

make anomalies appear like ordinary activity.

This application provides solutions for using a trained ANN to quickly and accurately identify anomalies as compared to anomaly detection performed using traditional methods.

The most significant underlying key variables are:

detection techniques, variation sensitivity, boundary definition - ordinary vs anomalous

Technology or Knowledge Base Level:

Activity #2-1: General anomaly detection - Ineligible (Fiscal Year 2024)

Methods of experimentation:

[Claim 2] A method of using an artificial neural network (ANN) comprising:
(a) receiving, at a computer, continuous training data;
(b) discretizing, by the computer, the continuous training data to generate input data;
(c) training, by the computer, the ANN based on the input data and a selected training algorithm to generate a trained ANN, wherein the selected training algorithm includes a backpropagation algorithm and a gradient descent algorithm;
(d) detecting one or more anomalies in a data set using the trained ANN;
(e) analyzing the one or more detected anomalies using the trained ANN to generate anomaly data; and
(f) outputting the anomaly data from the trained ANN.

A conventional backpropagation algorithm and a conventional gradient descent algorithm may be used to train the neural network. Gradient descent is an optimization algorithm used to minimize differentiable real-valued multivariate functions. Gradient descent begins by initializing the values of parameters and then applying a gradient descent calculation, which uses mathematical calculations to iteratively adjust the values so they minimize a loss function to optimize the ANN. Backpropagation is the mathematical process of calculating the derivatives and gradient descent is the process of adjusting model parameters using the calculated derivatives to minimize the loss function. Backpropagation is a mathematical calculation for supervised learning of ANNs using gradient descent. Given an ANN and an error function, backpropagation is used to calculate the gradient of the error function with respect to the neural network's weights.

Results:

Steps (a), (b), and (c) are all recited as being performed by a computer. The recited computer is recited at a high level of generality, i.e., as a generic computer performing generic computer functions.

Step (d) recites detecting one or more anomalies in a data set using the trained ANN. The claim does not provide any details about how the trained ANN operates or how the detection is made, and the plain meaning of "detecting" encompasses mental observations or evaluations, e.g., a computer programmer's mental identification of an anomaly in a data set.

The claim does not put any limits on how the continuous data is received, but the background supports the plain meaning of "receiving" as encompassing receiving the data remotely over a network.

The claim also does not limit the plain meaning of "discretizing," which, as explained in the background, includes any known discretization method, including binning and clustering, as well as numerical discretization, such as rounding continuous data values or performing other basic mathematical calculations that can be performed mentally (see the third paragraph of the background).

Step (c) recites training an ANN using a selected algorithm. The training algorithm is a backpropagation algorithm and a gradient descent algorithm. When given their broadest reasonable interpretation in light of the background, the backpropagation algorithm and gradient descent algorithm are mathematical calculations.

The plain meaning of these terms are optimization algorithms, which compute neural network parameters using a series of mathematical calculations.

The fourth paragraph of the background supports the plain meaning by stating the "gradient descent begins by initializing the values of parameters and then applying a gradient descent calculation, which uses mathematical calculations to iteratively adjust the values so they minimize a loss function."

Conclusion:

The trained ANN is used to generally apply the abstract idea without placing any limits on how the trained ANN functions. Rather, these limitations only recite the outcome of "detecting one or more anomalies" and "analyzing the one or more

Available for public distribution and use.

detected anomalies" and do not include any details about how the "detecting" and "analyzing" are accomplished. See MPEP 2106.05(f).

AUTHORS NOTE: THIS OUTLINES SOME POTENTIAL DOCUMENTATION ISSUES AND OPPORTUNITIES FOR SRED CLAIMS AS WELL AS PATENTS.

Activity #2-2: Packet method for security - Eligible (Fiscal Year 2024)

Methods of experimentation:

[Claim 3] A method of using an artificial neural network (ANN) to detect malicious network packets comprising:

(a) training, by a computer, the ANN based on input data and a selected training algorithm to generate a trained ANN, wherein the selected training algorithm includes a backpropagation algorithm and a gradient descent algorithm;
(b) detecting one or more anomalies in network traffic using the trained ANN;
(c) determining at least one detected anomaly is associated with one or more malicious network packets;
(d) detecting a source address associated with the one or more malicious network packets in real time;
(e) dropping the one or more malicious network packets in real time; and
(f) blocking future traffic from the source address.

Results:

- Malicious attack detection: 99.5 % (86% of goal)

Specifically, "detecting one or more anomalies in network traffic" is a mental process because the claimed detection is a process that is practically performed in the human mind by a human observing network traffic data and using "evaluation, judgment, and opinion" to detect whether an anomaly has occurred

"Unless it is clear that a claim recites distinct exceptions, such as a law of nature and an abstract idea, care should be taken not to parse the claim into multiple exceptions, particularly in claims involving abstract ideas." MPEP 2106.04, subsection II.B (discussing Bilski v. Kappos, 561 U.S. 593 (2010)).

Here, step (a) recites a mathematical concept, and steps (b) and (c) recite mental processes; therefore, claim 3 recites multiple abstract ideas. As discussed above for claim 2, in this case, it is appropriate to consider the limitations together as a single abstract idea rather than as a plurality of separate abstract ideas to be analyzed individually.

Limitations (d)-(f) do not recite mental processes because they cannot be practically performed in the human mind. That is, the human mind is not equipped to detect a source address associated with malicious network packets, drop the malicious network packets in real time, and block future traffic as recited in the claim. See MPEP 2106.04(a)(2), subsection III.A (discussing SRI Int'l, Inc. v. Cisco Systems, Inc., 930 F.3d 1295, 1303 (Fed. Cir. 2019)).

As step (a) and steps (b)-(c) fall within different groupings of abstract ideas (i.e., mathematical concepts and mental processes, respectively), these limitations are considered together as a single abstract idea for further analysis.

Conclusion:

The additional elements in steps (d)-(f), when considered in combination, integrate the abstract idea into a practical application because the claim improves the functioning of a computer or technical field. See MPEP 2106.04(d)(1) and 2106.05(a).

The claimed invention reflects this improvement in the technical field of network intrusion detection. Thus, the claim as a whole integrates the judicial exception into a practical application (Step 2A, Prong Two: YES), such that the claim is not directed to the judicial exception. (Step 2A: NO).

The claim is eligible.

AUTHORS NOTE: THE PATENT RULES PROVIDE ELIGIBILITY AS A RESULT OF IMPROVING A "PRODUCT" (FUNCTIONING OF A COMPUTER) . IN THE CASE OF HARDWARE / SOFTWARE THIS MAY PROVIDE SOME LESSONS FOR SR&ED RELATED CLAIMS - I.E. FOCUS ON IMPROVED PRODUCTS VS PROCESSES?

Significant variables addressed: boundary definition - ordinary vs anomalous, detection techniques, variation sensitivity

Available for public distribution and use.

Project Name:	AI Fibrosis Treatment	**Start Date:**	2024-03-04
Project Number:	2402	**Completion Date:**	2024-09-30

Project Details:

Scientific or Technological Objectives:

Measurement	Current Performance	Objective	Has results?
System to identify risk (%)	90	99.5	Yes
develop anti fibrotic eye drop (0= no / 1 = yes)	0	1	Yes
Reduce Post Inflammation (%)	60	90	Yes

Applicant developed a new anti-fibrotic drug, Compound X, that effectively reduces scarring around a microstent implantation site in glaucoma patients at high risk of PI after microstent implant surgery without the undesirable side effects of drug A. In connection with this invention, the applicant filed a patent application disclosing Compound X and describing how it may be topically administered in eye drop form after microstent implant surgery.

The applicant also discovered that PI is a polygenic condition, meaning that it results from the interaction of multiple genes rather than any single gene. Using standard methodologies, the applicant conducted a large-scale genome wide association (GWA) study on PI in glaucoma patients and identified 37 informative single-nucleotide polymorphisms (SNPs) that have a statistically significant association with PI. The application defines “informative SNPs” as the 37 SNPs identified in the GWA study. These informative SNPs serve as genetic markers for the genes that give rise to PI.

Field of Science/Technology:

Pharmacogenomics, gene-based therapeutics (3.04.04)

Project Details:

Intended Results:	Develop new processes, Develop new materials, devices, or products
Work locations:	Research Facility
Key Employees:	
Evidence types:	

Scientific or Technological Advancement:

Uncertainty #1: Technological uncertainty

Glaucoma is a leading cause of blindness globally. The most common form is open angle glaucoma, in which irreversible vision loss results from cell and optic nerve damage caused largely by poor drainage of aqueous humor from the eye. Depending on condition severity and the timing of the diagnosis, treatment can include lifestyle adjustments, pharmaceutical eye drops, laser eye surgery, or drainage device implants to facilitate healthy drainage.

While newer drainage devices, such as microstents, are more comfortable than earlier drainage devices, post-surgery scarring and inflammation due to fibrosis remain issues. Commonly prescribed anti-fibrotic drugs, such as drug A, can reduce scarring but do so non-specifically while causing more inflammation (“post-implantation inflammation” or “PI”) that further damages the eye.

The most significant underlying key variables are:

treatments - drops, microstints, surgery, modelling SNPs - AI (unresolved), drop formulation

Technology or Knowledge Base Level:

Activity #1-1: Screening method AI based - Ineligible (Fiscal Year 2024)

Available for public distribution and use.

Project Name:	AI Fibrosis Treatment	**Start Date:**	2024-03-04
Project Number:	2402	**Completion Date:**	2024-09-30

Methods of experimentation:

[Claim 1] A post-surgical fibrosis treatment method comprising:
(a) collecting and genotyping a sample from a glaucoma patient to a provide a genotype dataset;
(b) identifying the glaucoma patient as at high risk of post-implantation inflammation (PI) based on a weighted polygenic risk score that is generated from informative single-nucleotide polymorphisms (SNPs) in the genotype dataset by an ezAI model that uses multiplication to weight corresponding alleles in the dataset by their effect sizes and addition to sum the weighted values to provide the score; and
(c) administering an appropriate treatment to the glaucoma patient at high risk of PI after microstent implant surgery.

From the GWA study data, the applicant developed a polygenic risk score (PRS) model by classic clumping and thresholding methods to provide a weighted PRS. As is known in the art, a PRS is a single value estimate of an individual's relative risk for a given phenotype or condition based on the individual's genotype.

In brief, after collecting a sample from a patient, the sample is sequenced and genotyped to provide a genotype dataset. Alleles in the genotype dataset corresponding to informative SNPs selected from the GWA study are identified, tallied, and weighted (using effect sizes derived from GWA study summary statistics as weights). A PRS is then generated as a sum of the weighted values. Sample collection, sequencing, and genotyping for the purposes of providing a genotype dataset may be carried out by conventional methods known in the art.

The applicant also discloses a computer-implemented machine learning model (referred to as "the ezAI model" for the purposes of this disclosure) and its clinical applications.

Given an input of a patient's genotype dataset, the ezAI model calculates a weighted PRS from informative SNPs in the dataset—using multiplication to weight corresponding alleles in the dataset by their effect sizes and addition to sum the weighted values.

Using the same weights and informative SNPs, the ezAI model improves upon the base PRS model by determining a risk score and providing a classification in less time.

Results:

- System to identify risk : 97 % (73% of goal)

The specification discloses a method of identifying glaucoma patients at high risk of PI using this PRS model. An identification of a patient as being at high risk of PI is made by ranking a weighted PRS once the score has been generated.

The application defines a "glaucoma patient at high risk of PI" as a glaucoma patient having a weighted PRS in the top quartile of PRS values when ranked against reference PRS values established during PRS model development.

The disclosure teaches that determining patient risk using a weighted PRS as disclosed and accordingly customizing treatment lends to better prognosis after implant surgery.

Limitation (b) also recites "a weighted PRS that is generated from informative SNPs in the genotype dataset by an ezAI model that uses multiplication to weight corresponding alleles in the dataset by their effect sizes and addition to sum the weighted values to provide the score."

this limitation requires a mathematical calculation. Namely, an arithmetic calculation (multiplication to weight alleles by their effect sizes and addition to sum the weighted values) is required to generate a weighted risk score. Limitation (b) hence recites a "mathematical calculation" and so falls into the "mathematical concepts" grouping of abstract ideas.

For instance, given a genotype dataset, a physician would identify, tally, and weight alleles corresponding to informative SNPs present in the dataset by their effect sizes, then sum the resulting values to generate a risk score. See MPEP 2106.04(a)(2), subsection I.C.

This limitation also falls into the "mental process" grouping because it requires an assessment of the genotype dataset in order to identify informative SNPs in evaluating patient risk. Moreover, the recited mathematical calculation is simple enough that it can be practically performed in the human mind.

Even if most humans would use a physical aid, like a pen and paper or a calculator, to make such calculations, the use of a physical aid would not negate the mental nature of this limitation.

Conclusion:

Available for public distribution and use.

The data gathering activities in limitation (a) are recited at a high level of generality and have been recognized by the courts as being routine laboratory techniques (analyzing DNA to provide sequence information or to detect allelic variants is conventional in the art); MPEP 2106.05(d), subsection II.

The specification otherwise only describes carrying out sample collection and genotyping by conventional methods.

Consequently the additional elements individually or in combination do not provide an inventive concept;

While the disclosure states that “the ezAI model improves upon the base PRS model by determining a risk score and providing a classification in less time,” there is no improvement to the functioning of a computer nor to any other technology.

At best, the claimed combination amounts to an improvement to the abstract idea of determining patient risk rather than to any technology. See MPEP 2106.05(a). Thus, even when considering the elements in combination, claim 1 as a whole does not integrate the recited exception into a practical application. (Step 2A, Prong Two: NO).

The claim is not eligible.

AUTHORS NOTE: THESE LIMITS RELATE TO RESULTS GENERATED BY THE AI SYSTEM INSTEAD OF ISSUES WHICH INVOLVED / REQUIRED "SIGNIFICANT INPUT" FROM THE HUMAN RESEARCHER.

Activity #1-2: Custom eyedrops - Eligible despite AI result (Fiscal Year 2024)

Methods of experimentation:

[Claim 2] The method of claim 1, wherein the appropriate treatment is Compound X eye drops.

From the GWA study data, the applicant developed a polygenic risk score (PRS) model by classic clumping and thresholding methods to provide a weighted PRS. As is known in the art, a PRS is a single value estimate of an individual’s relative risk for a given phenotype or condition based on the individual’s genotype.

In brief, after collecting a sample from a patient, the sample is sequenced and genotyped to provide a genotype dataset. Alleles in the genotype dataset corresponding to informative SNPs selected from the GWA study are identified, tallied, and weighted (using effect sizes derived from GWA study summary statistics as weights).

A PRS is then generated as a sum of the weighted values. Sample collection, sequencing, and genotyping for the purposes of providing a genotype dataset may be carried out by conventional methods known in the art.

Results:

- develop anti fibrotic eye drop: 1 0= no / 1 = yes (100% of goal) -- Successful product
- Reduce Post Inflammation: 93 % (110% of goal)

An abstract idea is used to identify the patient as belonging to a specific patient population (glaucoma patients at high risk of PI), and the patient is then administered a treatment (Compound X eye drops instead of any common anti-fibrotic treatment, such as drug A, after microstent implant surgery) that is particular to that specific patient population (glaucoma patients at high risk of PI).

Relying on the determination of patient risk to administer Compound X eye drops to glaucoma patients at high risk of PI after microstent implant surgery is therefore a particular treatment for a medical condition such that the claim as a whole integrates the judicial exception into a practical application. See MPEP 2106.04(d)(2). (Step 2A, Prong Two: YES).

Conclusion:

The claim is eligible.

AUTHORS NOTE: USE OF AI RESULTS TO CREATE NEW PRODUCT WHICH IS ELIGIBLE FOR PATENT.

AUTHORS NOTE: THE PATENT RULES PROVIDE ELIGIBILITY AS A RESULT OF IMPROVING A "PRODUCT" (DEVELOPMENT OF THE NEW EYE DROP FORMULATION) .

IN THE CASE OF LIFE SCIENCES THIS MAY PROVIDE SOME LESSONS FOR SR&ED RELATED CLAIMS - I.E. FOCUS ON NEW/IMPROVED PRODUCTS VS. PROCESSES?

Significant variables addressed: drop formulation, treatments - drops, microstints, surgery

Available for public distribution and use.

Project Name:	Transaxle design using AI	**Start Date:**	2024-01-01
Project Number:	2410	**Completion Date:**	2024-12-31

Project Details:

Scientific or Technological Objectives:

Field of Science/Technology:

Mechanical engineering (2.03.01)

Project Details:

Intended Results: Develop new materials, devices, or products
Work locations: Research Facility
Key Employees:
Evidence types:

Scientific or Technological Advancement:

Uncertainty #1: Technological uncertainty

Technology or Knowledge Base Level:

Activity #1-1: AI generated result - Ineligible (Fiscal Year 2024)

Methods of experimentation:

Ruth and Morgan's contribution Analysis of the contribution
Recognized a problem (needing a transaxle) GP2-
Prompted the AI system to solve the problem
Reviewing the AI output

Results:

Conclusion:

GP3 - Recognition and appreciation of an invention without a contribution to conception is not sufficient.

Recognition of a problem does not rise to the level of Conception Prompt is only a restatement of the problem, no inventive contribution in how the prompt is constructed

Activity #1-2: Transaxle to practice - Ineligible (Fiscal Year 2024)

Methods of experimentation:

proof of concept prototype

Ruth and Morgan's contribution
Selected steel for the building the design: Selection of a well-known material is insignificant in quality when compared to the full scope of the claimed invention. (Second Pannu factor)

Morgan Recognized a problem; Prompted the AI system to solve the problem; Reviewing the AI output
As in scenario 1, Ruth and Morgan's contributions to identifying a problem and prompting Puerto5 to solve the problem are not significant.

Reduced the transaxle to practice
GP 3- Reducing an invention to practice alone is not a significant contribution that rises to inventorship

Available for public distribution and use.

Results:

Conclusion:

Activity #1-3: Redesign on horizontal plane - Eligible (Fiscal Year 2024)

Methods of experimentation:

Ruth and Morgan's Contribution
Created the new design based upon a suggestion from the AI system including:
• Elongated case
• Specific placement of elements in cases
• Specific location of separation in casing

Results:

GP 1 – a natural person's use of an AI system in creating an AI-assisted invention does not negate the person's contributions as an inventor
Clip fastener (Morgan) Original design by a natural person and a significant element of the claimed invention

Conclusion:

Activity #1-4: AI input on fabrication - Eligible (Fiscal Year 2024)

Methods of experimentation:

Results:

Conclusion:

Activity #1-5: AI system designer - Ineligible inventor (Fiscal Year 2024)

Methods of experimentation:

Results:

Conclusion:

Available for public distribution and use.

Project Name:	Therapeutic cancer compound using AI	**Start Date:**	2024-01-01
Project Number:	2411	**Completion Date:**	2024-12-31

Project Details:

Scientific or Technological Objectives:

Field of Science/Technology:

Health-related biotechnology (3.04.01)

Project Details:

Intended Results:	Develop new materials, devices, or products
Work locations:	Research Facility
Key Employees:	
Evidence types:	

Scientific or Technological Advancement:

Uncertainty #1: Technological uncertainty

Technology or Knowledge Base Level:

Activity #1-1: AI provided feedback - Eligible (Fiscal Year 2024)

Methods of experimentation:

Results:

Conclusion:

Activity #1-2: AI provided solution - Ineligible (Fiscal Year 2024)

Methods of experimentation:

Results:

Conclusion:

Available for public distribution and use.